Dendritic cells in cancer immunotherapy
Dendritic cells in cancer immunotherapy
复制标题
DOI：
10.1002/eji.201040630
复制
发表时间：
2010-08-01
影响因子：
5.4
通讯作者：
Schuler, Gerold
中科院分区：
文献类型：
--
作者：
Schuler, Gerold
DC启动和调节t细胞免疫，因此是优化所有类型疫苗的关键。深入了解DC生物学为增强免疫原性提供了许多机会。在本观点中，我将讨论与癌症疫苗临床开发直接相关的一些最新进展和发现。此外，我强调我个人的观点，即我们应该通过进行针对关键变量的双臂试验和通过mrna转染的DC传递抗原，探索过继转移DC（即DC疫苗）作为癌症疫苗的潜力。
DC initiate and regulate T-cell immunity and are thus the key to optimization of all types of vaccines. Insights into DC biology offer many opportunities to enhance immunogenicity. In this Viewpoint, I discuss some recent developments and findings that are of immediate relevance for the clinical development of cancer vaccines. In addition, I emphasize my personal view that we should explore the potential of adoptively transferred DC (i.e. DC vaccination) as cancer vaccines by performing two-armed trials that address critical variables and by delivering antigens via mRNA-transfected DC.